Medical Economics January 20, 2025
Todd Shryock

Key Takeaways

  • The Farapulse PFA System showed a 2.3% adverse event rate and 63.5% effectiveness in the Advantage AF study for persistent AF.
  • Symptomatic AF recurrence-free rates reached 91.8% for experienced physicians, with no major complications reported.
  • The Watchman FLX device reduced non-procedural bleeding by 44% and 62% for concomitant and sequential implantation, respectively, compared to oral anticoagulants.
  • Boston Scientific aims to improve AF patient outcomes by providing safer, more effective treatment options, enhancing quality of life and long-term health.

Boston Scientific showcases promising data on heart treatments at AF Symposium 2025

Boston Scientific Corp highlighted its advancements in treating atrial fibrillation with its Farapulse Pulsed Field Ablation System and the Watchman FLX Left Atrial Appendage Closure Device...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Medical Devices, Provider
Related Articles:
Biocompatible Nanoparticles: Tiny Antennae with Huge Potential for Brain-Computer Interfaces
Building Solid Relationships with Universities Critical for Early Stage Medtech Investors
Teleflex to split in 2, buy Biotronik assets for $791M among slew of actions
Thermo Fisher Beefs Up in Bioprocessing With $4B Acquisition of Solventum Biz Segment
Canon Healthcare investing $34M to open new US headquarters, imaging resource center

Share This Article